This website uses a limited number of cookies to improve your browsing experience. For further information (including how to withdraw consent), please refer to our Cookie Policy. By clicking Accept below or continuing to use this website (including closing this message), you confirm that you have read and consent to our use of cookies as detailed in our Cookie Policy.
UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA® (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn’s Disease
UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA® (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn’s Disease